COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study

[1]  B. McCrindle,et al.  Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children , 2023, JAMA network open.

[2]  S. Paul,et al.  Do we need to vaccinate every child against COVID-19: What evidence suggests—A systematic review of opinions , 2022, Frontiers in Public Health.

[3]  S. Mallapaty.  COVID jabs for kids: they’re safe and they work — so why is uptake so patchy? , 2022, Nature.

[4]  M. Karabacak,et al.  Frequency and safety of COVID-19 vaccination in children with multisystem inflammatory syndrome: a telephonic interview-based analysis , 2022, World Journal of Pediatrics.

[5]  A. Randolph,et al.  BNT162b2 mRNA Vaccination Against COVID-19 is Associated with Decreased Likelihood of Multisystem Inflammatory Syndrome in U.S. Children Ages 5–18 Years , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  O. Villate,et al.  Safety and Acceptance of COVID-19 Vaccination After Multisystem Inflammatory Syndrome in Children (MIS-C) in Spain , 2022, Journal of the Pediatric Infectious Diseases Society.

[7]  O. Watson,et al.  Global impact of the first year of COVID-19 vaccination: a mathematical modelling study , 2022, The Lancet Infectious Diseases.

[8]  C. Almqvist,et al.  Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children , 2022, The Lancet regional health. Europe.

[9]  J. Bullard,et al.  Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children. , 2022, Pediatrics.

[10]  I. Shavit,et al.  Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel. , 2022, JAMA.

[11]  F. Haerynck,et al.  SARS-CoV-2 vaccination in children with a history of MIS-C: an international survey , 2022, The Journal of Pediatrics.

[12]  A. Pottegård,et al.  Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study , 2022, BMJ.

[13]  A. Pariente,et al.  Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study , 2022, The Lancet Regional Health - Europe.

[14]  Michael P Miller,et al.  Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination , 2022, Emerging infectious diseases.

[15]  S. Volpi,et al.  Outcomes After SARS-CoV-2 Vaccination Among Children With a History of Multisystem Inflammatory Syndrome , 2022, JAMA network open.

[16]  M. Askenazi,et al.  Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19 , 2022, Nature Medicine.

[17]  Allan W. Taylor,et al.  Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation , 2022, The Lancet Child & Adolescent Health.

[18]  L. Zühlke,et al.  The clinical features and estimated incidence of MIS-C in Cape Town, South Africa , 2022, BMC Pediatrics.

[19]  A. Randolph,et al.  Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 , 2022, MMWR. Morbidity and mortality weekly report.

[20]  K. Ludwikowska,et al.  Guidelines for immunization of children following multisystem inflammatory syndrome in children , 2022, Pediatria Polska.

[21]  D. Shay,et al.  COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. , 2021, MMWR. Morbidity and mortality weekly report.

[22]  Abobakr A. Abdelgalil,et al.  Multisystem Inflammatory Syndrome in a 12-Year-old Boy After mRNA-SARS-CoV-2 Vaccination , 2021, The Pediatric infectious disease journal.

[23]  G. Tanır,et al.  A Case of Multisystem Inflammatory Syndrome in a 12-Year-old Male After COVID-19 mRNA Vaccine , 2021, The Pediatric infectious disease journal.

[24]  E. Cetin,et al.  Incidence of MIS-C and the Comorbidity Scores in Pediatric COVID-19 Cases. , 2021, Pediatrics international : official journal of the Japan Pediatric Society.

[25]  M. Zaniew,et al.  Distinct characteristics of multisystem inflammatory syndrome in children in Poland , 2021, Scientific Reports.

[26]  M. Rämet,et al.  Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age , 2021, The New England journal of medicine.

[27]  R. Buchhorn,et al.  Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? , 2021, Vaccines.

[28]  S. Lapp,et al.  SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19 , 2021, Nature Immunology.

[29]  U. Demkow,et al.  Recurrent assessment of lymphocyte subsets in 32 patients with multisystem inflammatory syndrome in children (MIS‐C) , 2021, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[30]  Kanwal M. Farooqi,et al.  Longitudinal Outcomes for Multisystem Inflammatory Syndrome in Children , 2021, Pediatrics.

[31]  K. Iyengar,et al.  Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V) , 2021, BMJ Case Reports.

[32]  C. Hoggart,et al.  Treatment of Multisystem Inflammatory Syndrome in Children , 2021, The New England journal of medicine.

[33]  B. Eley.  Faculty Opinions recommendation of Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[34]  Manish M Patel,et al.  Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 , 2021, JAMA network open.

[35]  P. Dormitzer,et al.  Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.

[36]  D. Walt,et al.  Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. , 2021, The Journal of clinical investigation.

[37]  J. Roliński,et al.  PIMS-TS, the New Paediatric Systemic Inflammatory Disease Related to Previous Exposure to SARS-CoV-2 Infection—“Rheumatic Fever” of the 21st Century? , 2021, International journal of molecular sciences.

[38]  M. Oster,et al.  Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study , 2021, The Lancet Child & Adolescent Health.

[39]  E. Wherry,et al.  Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19 , 2021, Science Immunology.

[40]  P. Moceri,et al.  Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data , 2021, Vaccine.

[41]  D. Ricke.  Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies , 2021, Frontiers in Immunology.

[42]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[43]  D. De Wolf,et al.  Acute Cardiovascular Manifestations in 286 Children with Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in Europe. , 2020, Circulation.

[44]  V. Pascual,et al.  The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges , 2020, Nature Medicine.

[45]  M. H. Cheng,et al.  Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation , 2020, Proceedings of the National Academy of Sciences.

[46]  E. Wherry,et al.  Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19 , 2020, medRxiv.

[47]  K. Wilson,et al.  Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) , 2020, Cell.

[48]  P. Palma,et al.  The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 , 2020, Cell.

[49]  K. Wilson,et al.  Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) , 2020, medRxiv.

[50]  Simon Li,et al.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.

[51]  David R. Holtgrave,et al.  Multisystem Inflammatory Syndrome in Children in New York State , 2020, The New England journal of medicine.

[52]  P. Davies,et al.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. , 2020, JAMA.

[53]  C. Delacourt,et al.  SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[54]  Angelo Mazza,et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.

[55]  P. Theocharis,et al.  Hyperinflammatory shock in children during COVID-19 pandemic , 2020, The Lancet.

[56]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[57]  H. Pan,et al.  Polish 2010 growth references for school-aged children and adolescents , 2010, European Journal of Pediatrics.